- Abstract Number: 2649
“Point of Care” Neurocognitive Testing for Neuropsychiatric Systemic Lupus Erythematosis (NPSLE)
- Abstract Number: 2435
‘It’s like the Worst Toothache You’ve Ever Had’ – How Persons with Rheumatoid Arthritis Describe and Manage Pain in Daily Life
- Abstract Number: L18
14-3-3eta Informs Joint Pathological Mechanisms of Treatment Response to Assist with T2T Strategies
- Abstract Number: 408
14-3-3η Auto-Antibody Positivity Informs Better Clinical Outcomes in RA
- Abstract Number: 359
14-3-3η Cit:Arg Antibody Ratios: Are We Overlooking the Prognostic Utility of Citrullinated Antibodies By Only Looking at Titers?
- Abstract Number: 362
14-3-3η Early RA Biomarkers: Does Seronegative RA Exist?
- Abstract Number: 405
14-3-3η: A Mechanistic Biomarker That Supports the Concept of “Uncoupling” of Inflammation and Joint Damage
- Abstract Number: 658
17β Estradiol Regulates VCAM-1 Expression during Glomerulonephritis
- Abstract Number: 465
18-Month Worldwide Post-Marketing Surveillance Experience of Tofacitinib
- Abstract Number: 2751
18F-FDG PET/CT in Vascular Disease Due to Behçet’s Syndrome
- Abstract Number: 667
24-Month Outcomes Associated with Belimumab in Patients with Systemic Lupus Erythematosus in Clinical Practice Settings
- Abstract Number: 1166
5 Year Budget Impact Analysis of Biosimilar Infliximab for the Treatment of Rheumatoid Arthritis in UK, Italy, France and Germany
- Abstract Number: 360
88% of Recent Onset Polyarthritis Patients Are Positive for 14-3-3η Markers and 14-3-3η Auto-Antibodies Inform a Favourable Prognosis
- Abstract Number: 885
A 2-Week Single-Blind, Randomized, 3-Arm Proof of Concept Study of the Effects of Secukinumab (anti-IL17 mAb), Canakinumab (anti-IL-1 b mAb), or Corticosteroids on Initial Disease Activity Scores in Patients with PMR, Followed By an Open-Label Extension to Assess Safety and Effect Duration
- Abstract Number: 776
A Candidate Gene Approach Identifies IL33 as a Novel Genetic Risk Factor for GCA
- 1
- 2
- 3
- …
- 202
- Next Page »